SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 95 400 KRW -2.25% Market Closed
Market Cap: 7.5T KRW
Have any thoughts about
SK Biopharmaceuticals Co Ltd?
Write Note

Operating Margin
SK Biopharmaceuticals Co Ltd

13.2%
Current
-13%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
13.2%
=
Operating Profit
67.3B
/
Revenue
511.3B

Operating Margin Across Competitors

Country KR
Market Cap 7.5T KRW
Operating Margin
13%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 710.5B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 3.3T DKK
Operating Margin
44%
Country US
Market Cap 373.5B USD
Operating Margin
28%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Country CH
Market Cap 202.7B CHF
Operating Margin
32%
Country CH
Market Cap 183.3B CHF
Operating Margin
31%
Country UK
Market Cap 162.4B GBP
Operating Margin
21%
Country IE
Market Cap 146B USD
Operating Margin
11%
No Stocks Found

SK Biopharmaceuticals Co Ltd
Glance View

Market Cap
7.5T KRW
Industry
Pharmaceuticals

SK Biopharmaceuticals Co Ltd., a prominent player in the global biopharmaceutical landscape, has carved out a niche in the development of innovative therapies for central nervous system (CNS) disorders. Founded in South Korea as a subsidiary of the SK Group, the company has swiftly gained recognition for its commitment to research and development, particularly in the realm of epilepsy treatments. Its flagship product, Cenobamate, has received approvals in various international markets, establishing a substantial revenue stream and bolstering SK Biopharmaceuticals’ reputation for tackling complex neurological conditions. This focus on underserved medical needs not only highlights the company’s scientific prowess but also reflects its strategic positioning within a growing market projected to expand significantly in the coming years. For investors, SK Biopharmaceuticals embodies a blend of growth potential and stability, driven by a robust pipeline of both established and novel therapies. The company is leveraging cutting-edge technology and extensive clinical research to explore additional indications for its existing products while continuing to develop new candidates. With a strong financial foundation and increasing market penetration, SK Biopharmaceuticals is poised to capitalize on the surging demand for innovative CNS treatments. As the company continues to expand its footprint globally, its commitment to quality, patient-centric approaches, and strategic partnerships will likely enhance shareholder value, making it an attractive consideration for those looking to invest in the biopharmaceutical sector.

Intrinsic Value
42 162.19 KRW
Overvaluation 56%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
13.2%
=
Operating Profit
67.3B
/
Revenue
511.3B
What is the Operating Margin of SK Biopharmaceuticals Co Ltd?

Based on SK Biopharmaceuticals Co Ltd's most recent financial statements, the company has Operating Margin of 13.2%.